Editorial Staff

Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

/in , , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Threats to intellectual property, political pressure to lower prices, disruption of clinical trials will cause long-term harm

BOSTON – Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.

“There will certainly be worldwide demand for COVID-19 treatments,” said William Smith, author of “The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector.”  “But they will also require massive investments in clinical development and manufacturing, and political pressure on pricing makes it impossible for companies to recoup those investments.”

Cipro is an antibiotic well-suited to treat anthrax, which began arriving in mailboxes in the weeks after September 11, 2001.  The Centers for Disease Control recommends that patients exposed to the bacteria take Cipro twice a day for 60 days.  Despite the fact that the entire course of treatment would only cost $219, Bayer agreed to cut the price in half after the U.S. Secretary of Health and Human Services at that time threatened to take away the company’s patent.

More recently, when Gilead announced it would invest $1 billion in Remdesivir, a promising COVID-19 treatment, one would have thought the company’s stock would rise.  Instead, it fell 5 percent.  A number of analysts remarked that the reason was fears that political pressure would result in very low prices or threats to Gilead’s patent.

Some investors and industry leaders may conclude that investments in major public health emergencies should be avoided in favor of research on lifestyle treatments or medications for less serious conditions that aren’t accompanied by threats to intellectual property or pressure to reduce prices.

Political pressure to cut prices is likely to be most acute in the area of vaccines, where the federal government is providing grants to companies such as Johnson & Johnson and Moderna.  Many policymakers will likely see any new vaccine that emerges from research that was partially funded by the government as public property.

“There may be humanitarian reasons why companies choose not to profit from their treatments,” said Pioneer Executive Director Jim Stergios.  “But policymakers should also be aware that threats to intellectual property create significant disincentives to investment.”

In 2018, Massachusetts institutions received nearly $3 billion in National Institutes of Health funding, the second highest amount among the states.  That same year, private venture companies invested $4.8 billion in the Commonwealth’s life sciences companies.  In terms of new businesses, more than a third of U.S.-based biotechs that went public in the first half of 2019 were Massachusetts-based.

These companies also face delays in clinical trials for non-COVID-19 treatments, which could significantly disrupt long-term product pipelines.  Since firms typically file patents before clinical trials begin, significant delays eat up the period during which treatments can be sold under patent before opening up to competition from generic makers.

The delays are particularly damaging to small firms, whose future may depend on a successful trial.

Smith’s recommendations include extending patent life on products by the period clinical trials were delayed by the pandemic, and that COVID-19 treatments in which companies made significant investments should be priced to allow a reasonable return on that investment.

About the Author

Dr. William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He writes about public policy issues impacting the life sciences industry with particular emphasis upon pharmaceuticals. Dr. Smith has 25 years of experience in government and in corporate roles. He spent ten years at Pfizer as Vice President of Public Affairs and Policy. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies, and was President of a small medical device company for three years. His career has also included senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Governor’s office in Massachusetts. He is affiliated as Research Fellow and Managing Director with the Center for the Study of Statesmanship at The Catholic University of America (CUA). He earned his PhD at CUA and a bachelor’s degree from Georgetown University.

About Pioneer

Mission
Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond.

Vision
Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values
Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibility, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Our COVID-19 News, Tips & Resources!

  • This field is for validation purposes and should be left unchanged.

Related Content

U-Arkansas Prof. Patrick Wolf on School Choice, Espinoza, & Students’ Civic Prep

0 Comments
/
U-Arkansas Prof. Patrick Wolf joins The Learning Curve to discuss school choice, the Supreme Court's Espinoza case, & students’ civic preparation.

COVID-19 Roundup from Pioneer: Hope for a vaccine; Open Meeting violations; Holyoke Soldiers Home report; COVID & foster care; Re-opening the beaches; the fate of college towns; COVID’s economic toll on Bay State cities & more!

0 Comments
/
Pioneer staff share their top picks for COVID-19 stories highlighting useful resources, best practices, and questions we should be asking our public and private sector leaders.

Announcing the Pioneer Institute & Nichols College Sports Management Policy College Case Competition

0 Comments
/
In recognition of the cancellation of many student internships…

Pulitzer Winner Diane McWhorter on Civil Rights History & Race in America

0 Comments
/
This week on “The Learning Curve,” Cara and Gerard mark the Juneteenth commemoration of the end of slavery with an episode devoted to Civil Rights history. They are joined by Diane McWhorter, the Pulitzer Prize-winning author of Carry Me Home: Birmingham, Alabama: The Climactic Battle of the Civil Rights Revolution.

Coronavirus Hits Back on Communities Who Slowed Their Spread

0 Comments
/
“This couldn’t come at a worse time,” said rep. Bill Keating…

Combatting COVID-19: Life in the MGH Emergency Room

0 Comments
/
Join host Joe Selvaggi and Pioneer Senior Fellow Josh Archambault as they talk with Dr. David King about the experience of being in emergent care during a pandemic and lockdown. They explore the challenges of coping with a poorly understood virus during a lockdown, all while continuing to serve the sick.

New Pioneer Institute Hotline Allows Public to Report Violations of Open Meeting Law

0 Comments
/
With most public meetings taking place remotely as a result of the COVID-19 pandemic, Pioneer Institute has unveiled an online hotline that allows members of the public to report potential violations of the Commonwealth’s and other states' Open Meeting Law.

Pandemic, Lost Instructional Time Reveal Massachusetts’ Digital Learning Weaknesses

A report released today by Pioneer Institute says that the shutdown of Massachusetts schools due to the COVID-19 virus and the shift to online education have exposed the uneven nature of digital learning in the Commonwealth, and calls for state officials to develop programs to create more consistency.

Pioneer Institute Study Calls for Streamlining State Sales Tax Revenue Collection

At a time when state tax revenues are plummeting, a plan to modernize sales tax collection could get money into state coffers more quickly, according to a new policy brief published by Pioneer Institute.

COVID-19 Roundup from Pioneer: Hubwonk: Elections & COVID-19; Update: Mapping COVID Testing; School Reopening; Protecting Civil Liberties, & more!

0 Comments
/
Pioneer staff share their top picks for COVID-19 stories highlighting useful resources, best practices, and questions we should be asking our public and private sector leaders.

Hubwonk Ep. 9: Elections in Epidemics: Keeping Voters Safe & Elections Fair during COVID-19

0 Comments
/
Join Joe Selvaggi and Pioneer’s Mary Connaughton as they talk with MIT Professor Charles Stewart on how states in general, and Massachusetts in particular, are adapting their voting process to keep elections safe, transparent, and fair during the COVID-19 pandemic.

Update: “Mapping COVID-19” Tool Now Shows Testing Data

0 Comments
/
Now, in addition to maps and tables regarding the number of cases and case rates across the state, “Mapping COVID-19” also includes information regarding the testing efforts in the Commonwealth.